4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
8.64
-0.29 (-3.25%)
Mar 5, 2026, 4:00 PM EST - Market closed
4D Molecular Therapeutics Employees
4D Molecular Therapeutics had 227 employees as of December 31, 2024. The number of employees increased by 80 or 54.42% compared to the previous year.
Employees
227
Change (1Y)
80
Growth (1Y)
54.42%
Revenue / Employee
$529
Profits / Employee
-$921,485
Market Cap
440.71M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 227 | 80 | 54.42% |
| Dec 31, 2023 | 147 | 7 | 5.00% |
| Dec 31, 2022 | 140 | 16 | 12.90% |
| Dec 31, 2021 | 124 | 41 | 49.40% |
| Dec 31, 2020 | 83 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| REGENXBIO | 353 |
| Entrada Therapeutics | 152 |
| Century Therapeutics | 150 |
| Solid Biosciences | 100 |
| Lineage Cell Therapeutics | 77 |
| Assembly Biosciences | 73 |
| Altimmune | 59 |
| Anavex Life Sciences | 34 |
FDMT News
- 14 days ago - 4DMT to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 20 days ago - 4DMT Announces New Employment Inducement Grants - GlobeNewsWire
- 24 days ago - 4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD - GlobeNewsWire
- 7 weeks ago - 4D Molecular Therapeutics, Inc. (FDMT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - 4DMT Provides Company Update and Anticipated Development Milestones for 2026 - GlobeNewsWire
- 2 months ago - 4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AEROW Trial in Cystic Fibrosis and Platform Potential Transcript - Seeking Alpha
- 2 months ago - 4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease - GlobeNewsWire
- 3 months ago - 4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire